Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients With Major Depressive Disorder.

IF 2.9 3区 医学 Q2 PHARMACOLOGY & PHARMACY
Andria L Del Tredici, Holly L Johnson, Brady DeHart, Alexander Gutin, Pamela Morin, Chelsea R Kasten, Laura Becker, Katherine Johansen Taber, Devika Chawla, Andrew A Nierenberg
{"title":"Real-World Impact of Pharmacogenomic Testing on Medication Use and Healthcare Resource Utilization in Patients With Major Depressive Disorder.","authors":"Andria L Del Tredici, Holly L Johnson, Brady DeHart, Alexander Gutin, Pamela Morin, Chelsea R Kasten, Laura Becker, Katherine Johansen Taber, Devika Chawla, Andrew A Nierenberg","doi":"10.1097/JCP.0000000000001999","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Pharmacogenomic (PGx) testing can help improve response and remission rates for patients with major depressive disorder (MDD) and at least one treatment failure. To investigate real-world outcomes, we examined 1) significant gene-drug interactions (GDIs) and 2) healthcare resource utilization (HRU) in a large US insurance claims dataset.</p><p><strong>Methods: </strong>Weighted multigene PGx testing results in adult patients with MDD were linked with deidentified US claims data. The PGx test report organized medications as congruent (no known or moderate GDI) or incongruent (significant GDI). Medication claims data before and after PGx testing was used to categorize patients as no change in congruency, incongruent-to-congruent, or congruent-to-incongruent. HRU (hospitalizations and emergency department visits) was compared in the 180 days before and after PGx testing.</p><p><strong>Results: </strong>A total of 20,933 patients met inclusion criteria; 16,965 of whom filled medication prescriptions before and after PGx testing. After PGx testing, the proportion of patients filling prescriptions with significant GDIs was reduced (26.1% pretesting vs 15.9% posttesting). All HRU was significantly reduced (P < 0.001) after PGx testing except for nonpsychiatric hospitalizations (P > 0.05). Psychiatric hospitalizations were significantly reduced after PGx testing in the incongruent-to-congruent and no change in congruency categories (P < 0.001), but not in the congruent-to-incongruent category. Conversely, emergency department visits were significantly reduced after PGx testing in all congruency categories (P < 0.005) and did not differ when compared across congruency categories.</p><p><strong>Conclusions: </strong>After PGx testing, patients with MDD had decreased prescribing of medications with significant GDI and reduced HRU. PGx testing may have influenced these outcomes, but the retrospective study design limits clarity on its impact.</p>","PeriodicalId":15455,"journal":{"name":"Journal of Clinical Psychopharmacology","volume":" ","pages":""},"PeriodicalIF":2.9000,"publicationDate":"2025-04-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Clinical Psychopharmacology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/JCP.0000000000001999","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Pharmacogenomic (PGx) testing can help improve response and remission rates for patients with major depressive disorder (MDD) and at least one treatment failure. To investigate real-world outcomes, we examined 1) significant gene-drug interactions (GDIs) and 2) healthcare resource utilization (HRU) in a large US insurance claims dataset.

Methods: Weighted multigene PGx testing results in adult patients with MDD were linked with deidentified US claims data. The PGx test report organized medications as congruent (no known or moderate GDI) or incongruent (significant GDI). Medication claims data before and after PGx testing was used to categorize patients as no change in congruency, incongruent-to-congruent, or congruent-to-incongruent. HRU (hospitalizations and emergency department visits) was compared in the 180 days before and after PGx testing.

Results: A total of 20,933 patients met inclusion criteria; 16,965 of whom filled medication prescriptions before and after PGx testing. After PGx testing, the proportion of patients filling prescriptions with significant GDIs was reduced (26.1% pretesting vs 15.9% posttesting). All HRU was significantly reduced (P < 0.001) after PGx testing except for nonpsychiatric hospitalizations (P > 0.05). Psychiatric hospitalizations were significantly reduced after PGx testing in the incongruent-to-congruent and no change in congruency categories (P < 0.001), but not in the congruent-to-incongruent category. Conversely, emergency department visits were significantly reduced after PGx testing in all congruency categories (P < 0.005) and did not differ when compared across congruency categories.

Conclusions: After PGx testing, patients with MDD had decreased prescribing of medications with significant GDI and reduced HRU. PGx testing may have influenced these outcomes, but the retrospective study design limits clarity on its impact.

药物基因组学检测对重度抑郁症患者药物使用和医疗资源利用的现实影响
背景:药物基因组学(PGx)检测可以帮助改善重度抑郁症(MDD)患者的反应和缓解率,并且至少有一次治疗失败。为了研究现实世界的结果,我们在一个大型美国保险索赔数据集中研究了1)显著的基因-药物相互作用(gdi)和2)医疗资源利用(HRU)。方法:成年重度抑郁症患者的加权多基因PGx检测结果与未识别的美国索赔数据相关联。PGx测试报告组织药物为一致(无已知或中度GDI)或不一致(显著GDI)。使用PGx测试前后的药物声明数据将患者分类为一致性、不一致到一致或一致到不一致没有变化。在PGx检测前后180天内比较HRU(住院和急诊就诊)。结果:共有20933例患者符合纳入标准;其中16,965人在PGx检测前后开了药。PGx检测后,gdi显著的患者配药比例降低(前测26.1% vs后测15.9%)。除非精神科住院患者外,PGx检测后所有HRU均显著降低(P < 0.001)。在不一致到一致的PGx测试后,精神科住院率显著减少,在一致类别没有变化(P < 0.001),但在一致到不一致类别没有变化。相反,在所有一致性类别中进行PGx测试后,急诊科就诊人数显着减少(P < 0.005),并且在一致性类别之间进行比较时没有差异。结论:经过PGx检测,MDD患者减少了GDI和HRU显著降低的药物处方。PGx检测可能影响了这些结果,但回顾性研究设计限制了其影响的清晰度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
4.00
自引率
3.40%
发文量
231
审稿时长
4-8 weeks
期刊介绍: Journal of Clinical Psychopharmacology, a leading publication in psychopharmacology, offers a wide range of articles reporting on clinical trials and studies, side effects, drug interactions, overdose management, pharmacogenetics, pharmacokinetics, and psychiatric effects of non-psychiatric drugs. The journal keeps clinician-scientists and trainees up-to-date on the latest clinical developments in psychopharmacologic agents, presenting the extensive coverage needed to keep up with every development in this fast-growing field.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信